Pasar al contenido principal

SEÑALIZACION POR RECEPTORES ERBB/HER

BES-2013-065223

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Formación
Convocatoria Contratos Predoctorales
Año convocatoria 2013
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Resistance to antibody–drug conjugates

  • García-Alonso, Sara
  • Ocaña, Alberto
  • Pandiella, Atanasio
Antibody–drug conjugates (ADC) are multicomponent molecules constituted by an antibody covalently linked to a potent cytotoxic agent. ADCs combine high target specificity provided by the antibody together with strong antitumoral properties provided by the attached cytotoxic agent. At present, four ADCs have been approved and over 60 are being explored in clinical trials. Despite their effectiveness, resistance to these drugs unfortunately occurs. Efforts to understand the bases underlying such resistance are being carried out with the final purpose of counteracting them. In this review, we report described mechanisms of resistance to ADCs used in the clinic along with other potential ones that may contribute to resistance acquisition. We also discuss strategies to overcome resistance to ADCs., This work was supported by the Ministry of Economy and Competitiveness of Spain (BFU2015-71371-R to A. Pandiella and BES-2013-065223 to S. GarcíaAlonso); the Junta de Castilla y Leon (CSI002U16); the Scienti fic Foundation of the AECC and the CRIS Foundation (to A. Pandiella). Work in A. Ocana~ laboratory is supported by the Instituto de Salud Carlos III (PI16/01121); ACEPAIN; Diputacion de Albacete; and the CRIS Cancer Foundation. The work carried out in our laboratories receives additional support from the European Community through the regional development funding program (FEDER).